$RMD

NZ sharemarket falls 0.96% as Middle East uncertainty lifts oil price – Market close

New Zealand shares fell 0.96% at the market close as Middle East uncertainty supported higher oil prices. Brent crude rose to US$83.77. Locally, Fisher & Paykel Healthcare, Auckland Airport, Infratil, a2 Milk and Contact Energy declined. T&G Global rose after reporting 2.6% revenue growth to $572.3m and operating profit of $11.6m. ResMed and other stocks also moved.

Original reporting
Published Aug 7, 2026, 6:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 6:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NZ sharemarket falls 0.96% as Middle East uncertainty lifts oil price – Market close — source image
Decision brief

The 30-second read

$RMDBearishMed
01

Why it matters

ResMed’s earnings miss is a direct negative catalyst for its own stock and a potential read-through risk for Fisher and Paykel ahead of its Aug 25 update. Heartland faces transaction risk from a High Court filing tied to the proposed TSB Bank sale and planned merger timeline.

02

Market read

This is a market-close wrap with a few actionable idiosyncratic items: ResMed’s earnings miss, T&G’s interim results, and Heartland’s legal filing affecting a pending bank sale.

03

What to watch

For Fisher and Paykel, the article cites research suggesting margin squeeze should not “kick through,” which could limit downside if investors overreact to ResMed’s issues.

Relevance 5/10Novelty 5/10Timing: market close wrap, with next week’s reporting season and Aug 25 Fisher and Paykel update in focus

Background

The piece frames a down NZ session amid Middle East negotiation uncertainty (Iran and Oman) and rising Brent, while highlighting upcoming NZ reporting season and specific company catalysts.

Company-level read

Ticker impact

$RMDBearishHigh confidence
Context

ResMed is described as missing fourth-quarter expectations with lower profit margin, EPS, and guidance, and shares down 7.64%.

Expected impact

Further downside risk if investors extrapolate product problems and margin compression beyond the quarter.

Evidence & confidence

The text explicitly states missed expectations and lower guidance plus “some product problems,” which typically drives immediate and follow-on selling.

$TGLBullishMedium confidence
Context

T&G Global shares rise after reporting 2.6% revenue growth to $572.3m and operating profit up 30.3% for the six months ending June.

Expected impact

Supportive for the stock near-term if investors focus on operating profit growth and apple sales strength.

Evidence & confidence

The article includes concrete financial figures and a specific operational detail about Envy apple sales, which can drive repricing.

Market effects

Shipping-route uncertainty around the Strait of Hormuz and higher Brent can swing sentiment across logistics and energy-linked NZ equities.

NZ equities are shown broadly lower (0.96%) while US indices are mixed-to-down, suggesting global risk sentiment spillover.

Iran-Oman negotiation uncertainty is linked to oil price moves, which can propagate to global energy and transport cost expectations.

Counterpoint

The NZ declines may be mostly macro and tape-driven; only ResMed’s earnings miss and Heartland’s legal filing are clearly company-specific catalysts.

Key entities

  • ResMed

    Fourth-quarter results missed expectations, with lower profit margin, EPS, and guidance plus product problems.

  • Fisher and Paykel Healthcare

    Investors will watch whether ResMed-driven margin pressure affects it ahead of an Aug 25 annual meeting update.

  • Heartland Group

    Says a High Court proceeding was filed against Toi Foundation regarding consultation and decision-making for the proposed TSB Bank sale.

  • T&G Global

    Reported six-month revenue and operating profit growth, including strong Envy apple sales to Asian markets.

Related articles

$RMDMedAI 8/10

Why is ResMed stock sliding today?

ResMed shares fell about 5.5% pre-open after the company reported mixed Q4 FY2026 results. Non-GAAP EPS was $2.95, above the ~$2.89 consensus, but revenue was $1.46B, slightly below ~$1.47B. ResMed’s first full-year FY2027 guidance implied 5–7% core revenue growth, plus a $75M Astral ventilator safety headwind, with MatrixCare divestiture and Noctrix acquisition expected to dilute EPS. Analysts cut price targets.

$RMDMed

CPAP machine maker posts record revenue but shares sink

ResMed, an ASX-listed CPAP maker, reported record Q4 revenue of US$1.5B and FY2025/26 revenue of US$5.7B, up 10%. Full-year net income rose 9% to US$1.5B, but gross margin was 62.3% versus 62.7% expected, which the company attributed to inflation. ResMed plans modest 2026/27 price increases. Shares fell 4.9% to $29.94.

$RMDMedAI 9/10

RESMED INC (RMD): Results of Operations and Financial Condition

RESMED INC (RMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d158732dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 investorrelations@resmed.com news@resmed.com Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 • Q4 revenue increased by 9% to a record $1.5 bil

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$RMDMed

ResMed Analyst Backs Portfolio Reset - ResMed (NYSE:RMD)

ResMed (RMD) is planning to divest its MatrixCare business as part of its 2030 strategy. MatrixCare generated about $220M revenue and $55M adjusted operating profit in fiscal 2026 prelims. The deal is expected to close in Q1 FY2027. ResMed’s Noctrix acquisition (June, $340M) is expected to add ~$30M revenue and reduce adjusted EPS by ~20 cents in FY2027.